Morgan Stanley Raises Guardant Health (GH) Price Target to $200

Morgan Stanley has reiterated its Overweight rating on Guardant Health with a new price target of $200, a 25.02% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:19 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley raised its price target on Guardant Health, Inc. ($GH) to $200 from $185 on October 13, 2026, and rates the stock "Overweight".

Since the rating, $GH is down 2.1% to date (from the $162.09 close on Oct 13, 2026).

GH Guardant Health, Inc.

$158.60 +55.89% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, Morgan Stanley maintained its Overweight rating on Guardant Health, Inc. with a price target of $200, up from $185.
Morgan Stanley's $200 price target implies 25.02% upside from Guardant Health, Inc.'s ($GH) current $159.97 share price.
As of October 16, 2026, Guardant Health traded recently around $159.97, which is 20% below the analyst's target.
Guardant Health's trailing twelve-month revenue stands at approximately $1.18 billion, despite a negative net margin of 38.3%.

Get $GH trade alerts by text

We text you when insiders, Congress or big funds trade $GH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures

Morgan Stanley has reiterated its Overweight rating on Guardant Health, Inc. (NASDAQ: GH) on October 13, 2026, raising its price target from $185 to $200. This target is now 20% above the recent trading price.

Morgan Stanley's Call on Guardant Health

Morgan Stanley's updated price target of $200 reflects its positive outlook on Guardant Health's growth potential. The firm has a long position in the stock and believes the company is well-positioned in the healthcare sector.

Other Institutional Activity in Guardant Health

Several other institutional investors have also adjusted their positions in Guardant Health. Blackrock Inc. reduced its holdings by 3,930,468 shares, ending with 7,622,935 shares worth about $1.21 billion. Price (T. Rowe) Associates Inc. trimmed its stake by 508,498 shares, bringing its total to 6,514,952 shares valued at approximately $1.03 billion. In contrast, FMR, LLC increased its holdings by 1,372,274 shares, totaling 5,488,272 shares worth about $870 million.

Guardant Health, Inc. Stock Down 3.6%

As of October 16, 2026, Guardant Health shares traded at $159.97. This price is below the new target set by Morgan Stanley, indicating potential for growth if the company's performance aligns with analyst expectations.

12-month forecast

$GH price target

Guardant Health, Inc. daily closes and this analyst's $200 target. Not advice.

Recent Earnings

Guardant Health reported trailing twelve-month revenue of $1.18 billion, reflecting a year-over-year growth of 44.3%. However, the company has a negative net margin of 38.3%, which indicates it is not currently profitable. The next earnings report is expected on October 28, 2026, which could provide further insights into its financial performance.

Insider Buying and Selling at Guardant Health, Inc.

Recent insider activity includes several sales. Darya Chudova, Chief Technology Officer, sold 7,738 shares at an average price of $178 on September 15, 2026, totaling about $1.38 million. Director Alex M Azar II sold 826 shares at $175 on September 16, 2026, for about $144,550. Additionally, Steve E Krognes, another director, sold 6,674 shares, valued at approximately $1.17 million, on the same day.

Analysts Set New Price Targets

On October 13, 2026, Morgan Stanley maintained its Overweight rating on Guardant Health with a price target of $200. This follows several other firms also providing price targets, including Barclays, which set a target of $220, and Guggenheim, which set a target of $200.

About Guardant Health

Guardant Health, Inc. is a precision oncology company based in Palo Alto, California. It specializes in providing blood and tissue tests, along with data sets, to aid in cancer detection and treatment. The company operates both in the United States and internationally, making significant strides in the diagnostics and research sector.

Bottom Line

Investors should keep an eye on Guardant Health's upcoming earnings date on October 28, 2026, for insights into its financial health. Additionally, watch for any changes in analyst ratings or price targets as the market reacts to the company's performance.